Sir, Molecular pathology tests have the potential to revolutionise the way cancer and other diseases are diagnosed and treated. However, as your report highlights, this chance is being missed by the NHS (“Doctors’ ignorance drives cancer lottery”, Aug 20). My experience is that pathologists are aware of the value of molecular testing but that the funding mechanisms to do so easily are not in place.
It is not essential for everyone treating cancer patients to be an expert in molecular diagnostics but it is fundamental that they have local, funded molecular diagnostic services to carry out tests when they are indicated. While continuing education of health professionals is important, investment in fully funded molecular services across the country is the key to providing cancer patients in the UK with the world-class diagnostic service they deserve.
dr suzy lishman
President, Royal College of Pathologists